No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDRm | 4,024,971 | 3,976,656 | 3,631,451 | 4,136,182 | 4,367,490 | 4,421,550 | N/A | N/A |
| Operating profit | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | IDRm | 113,697 | 105,043 | -950,289 | 70,460 | 86,599 | 123,698 | N/A | N/A |
| EPS reported | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PT Kino Indonesia Tbk manufactures and distributes a diverse range of consumer products both domestically within Indonesia and across international markets. Its extensive portfolio includes personal care items, various beverages, food products, pharmaceutical goods, and pet food. The company's personal care offerings encompass haircare solutions under brands like Ellips, Sasha, and Samantha; oral hygiene products such as Sasha and Click; skincare items including Ovale and Ristra; baby care essentials via Sleek Baby; cosmetics from Abstract; fragrances under Eskulin; and feminine hygiene products like Resik V and Absolute. It also caters to children's personal care needs with B&B Kids, Eskulin Kids, and Master Kids, and provides men's grooming products through the Master brand. Additionally, its personal care segment features air fresheners (Evergreen), hygiene products like hand sanitizers (Sleek, Instance Hand Sanitizer), and pet foods marketed under the MAXLife brand. In the beverage sector, PT Kino Indonesia offers remedy drinks (Cap Kaki Tiga, Larutan Sejuk Segar), health-focused beverages (Cap Panda), energy drinks (Panther), and a selection of canned fruits, coconut water, and juices from the Malee brand. Its food division includes confectionery, such as candies under Kino Candy, Oplozz, Frenta Candy, and Chew Chew Ball, alongside snacks like Kino Naster and Snack It, and powdered drink mixes from the Segar Sari brand. Furthermore, the company produces pharmaceutical items, including herbal cough medicines, balms, headache relief, and ringworm treatments (Cap Kaki Tiga, Q-Life), as well as general herbal products under the Dua Putri Dewi brand. Established in 1999, the company, previously known as PT Kinocare Era Kosmetindo, maintains its headquarters in Tangerang, Indonesia, and operates as a subsidiary of PT Kino Investindo.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
PT Kino Indonesia Tbk (KINO.JK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
PT Kino Indonesia Tbk manufactures and distributes a diverse range of consumer products both domestically within Indonesia and across international markets. Its extensive portfolio includes personal care items, various beverages, food products, pharmaceutical goods, and pet food. The company's personal care offerings encompass haircare solutions under brands like Ellips, Sasha, and Samantha; oral hygiene products such as Sasha and Click; skincare items including Ovale and Ristra; baby care essentials via Sleek Baby; cosmetics from Abstract; fragrances under Eskulin; and feminine hygiene products like Resik V and Absolute. It also caters to children's personal care needs with B&B Kids, Eskulin Kids, and Master Kids, and provides men's grooming products through the Master brand. Additionally, its personal care segment features air fresheners (Evergreen), hygiene products like hand sanitizers (Sleek, Instance Hand Sanitizer), and pet foods marketed under the MAXLife brand. In the beverage sector, PT Kino Indonesia offers remedy drinks (Cap Kaki Tiga, Larutan Sejuk Segar), health-focused beverages (Cap Panda), energy drinks (Panther), and a selection of canned fruits, coconut water, and juices from the Malee brand. Its food division includes confectionery, such as candies under Kino Candy, Oplozz, Frenta Candy, and Chew Chew Ball, alongside snacks like Kino Naster and Snack It, and powdered drink mixes from the Segar Sari brand. Furthermore, the company produces pharmaceutical items, including herbal cough medicines, balms, headache relief, and ringworm treatments (Cap Kaki Tiga, Q-Life), as well as general herbal products under the Dua Putri Dewi brand. Established in 1999, the company, previously known as PT Kinocare Era Kosmetindo, maintains its headquarters in Tangerang, Indonesia, and operates as a subsidiary of PT Kino Investindo.